Amyloidosis Therapeutics Market Growth Outlook Highlighted by Persistence Market Research

Amyloidosis, a rare but serious disease, is characterized by the abnormal deposition of amyloid proteins in various organs such as the heart, kidneys, liver, and nervous system. This condition can lead to severe complications, including organ failure, if not treated early. As a result, the amyloidosis therapeutics market has been witnessing significant growth, driven by rising disease awareness, early diagnosis, and advancements in targeted therapies. According to Persistence Market Research, the global amyloidosis therapeutics market is projected to reach a market size of approximately US$ 8.20 billion by 2032, growing at a CAGR of 6.8% from US$ 5.17 billion in 2025.

This article explores the key factors propelling the growth of the amyloidosis therapeutics market, including market statistics, key drivers, growth segments, and the regions leading the charge. It also examines the challenges the market faces, such as high treatment costs, and discusses the innovative treatment opportunities, particularly through the use of artificial intelligence (AI).

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35504

Overview of the Market

The amyloidosis therapeutics market is primarily driven by an increase in the prevalence of the disease and improvements in diagnostic and treatment methodologies. Amyloidosis occurs when amyloid proteins misfold and accumulate in tissues and organs, impairing their normal functions. These proteins are categorized into several types, including AL amyloidosis (primary amyloidosis), AA amyloidosis (secondary), transthyretin amyloidosis (ATTR), hereditary amyloidosis, and localized amyloidosis.

Recent advancements in diagnostic technologies, such as cardiac MRI and biopsy-based testing, have led to earlier detection and better management of amyloidosis. Innovations in chemotherapy, immunosuppressive drugs, and personalized medicine are contributing to more effective treatments. This has spurred the growth of the global amyloidosis therapeutics market, as more patients are diagnosed and treated at an earlier stage.

Market Statistics and Key Growth Drivers

The amyloidosis therapeutics market is projected to grow from US$ 5.17 billion in 2025 to US$ 8.20 billion by 2032, representing a CAGR of 6.8% over the forecast period. Key growth drivers behind this market expansion include:

Rising Prevalence of Amyloidosis: As populations age, amyloidosis diagnoses are becoming more common, especially in elderly patients who are prone to systemic amyloid deposits, including cardiac amyloidosis (CA).

Advancements in Early Detection: The development of highly accurate diagnostic methods is allowing for the identification of amyloidosis at earlier stages, improving the success rate of treatments.

Innovative Drug Development: The emergence of newer therapeutics such as lenalidomide, pomalidomide, and daratumumab has provided effective alternatives for treating amyloidosis, particularly AL amyloidosis.

The chemotherapy segment currently holds a significant market share, expected to dominate the market with 33% of the share by 2025. On the other hand, immunosuppressive drugs and targeted therapies are expected to be the fastest-growing segments due to their efficacy in treating different types of amyloidosis, especially in combination with stem cell transplantation or chemotherapy.

Leading Segments and Geographical Insights

Among the major segments in the amyloidosis therapeutics market, chemotherapy is anticipated to maintain its leadership, particularly in AL amyloidosis, where therapies like melphalan combined with stem cell transplantation are the standard treatment. Additionally, hospitals and clinics are expected to be the largest end-users in 2025, accounting for around 51% of the market share.

Geographically, North America is poised to dominate the amyloidosis therapeutics market, accounting for approximately 47% of the market share by 2025. This dominance is attributed to robust healthcare infrastructure, increasing awareness of amyloidosis, and approval of novel treatments. The U.S. market, in particular, is experiencing rapid growth due to the approval of Amvuttra (vutrisiran) for ATTR-CM and Acoramidis (Beyonttra) for transthyretin amyloid cardiomyopathy (ATTR-CM).

Key Highlights from the Report

• The chemotherapy segment is expected to capture 33% of the market share by 2025.
• Hospitals & clinics will dominate the amyloidosis therapeutics market in 2025, accounting for 51% of the share.
• North America will hold a substantial 47% share of the market by 2025, driven by advanced healthcare systems and disease awareness.
• The growing adoption of immunosuppressive drugs such as lenalidomide and pomalidomide is driving market growth.
• AI technologies in imaging, particularly cardiac MRI and nuclear scans, are significantly improving diagnostic accuracy.
• The home care segment is gaining momentum, especially in North America and Europe, as patients prefer more convenient treatment options.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/amyloidosis-therapeutics-market.asp

Market Segmentation

The amyloidosis therapeutics market is segmented into treatment type and end-user, among other categories. Below is a detailed breakdown of the market segmentation:

By Treatment Type

The chemotherapy segment dominates the amyloidosis therapeutics market, particularly for AL amyloidosis. High-dose chemotherapy using melphalan, combined with autologous stem cell transplant (ASCT), remains the standard treatment option. Other novel agents, including proteasome inhibitors like bortezomib, and immunomodulatory drugs like lenalidomide and pomalidomide, are expected to see rapid adoption due to their ability to suppress abnormal plasma cell clones.

Additionally, the immunosuppressive drugs segment is expected to experience the fastest growth during the forecast period. Drugs like dexamethasone, lenalidomide, and pomalidomide are increasingly becoming integral parts of combination regimens to control the plasma cell clone responsible for amyloid production.

By End-User

The hospitals and clinics segment is expected to hold the largest share of the amyloidosis therapeutics market by 2025. Hospitals are well-equipped with advanced diagnostic tools and specialized treatments, such as chemotherapy, immunotherapy, and stem cell transplantation, making them the preferred setting for amyloidosis care.

However, the home care segment is experiencing rapid growth, especially in North America and Europe. Home care services, including telemedicine and remote patient monitoring, allow patients to manage their condition from the comfort of their homes. Hospitals and home care providers often collaborate to ensure continuity of care, especially for patients requiring long-term treatment.

Regional Insights
North America

The North American amyloidosis therapeutics market is expected to lead the global market in 2025, driven by significant advancements in diagnostics, a high level of disease awareness, and comprehensive healthcare systems. The U.S. market is particularly growing due to innovations like AI-powered imaging tools and the FDA approvals of therapies like Amvuttra and Acoramidis. Furthermore, the growing trend of telemedicine and home care solutions in the U.S. is contributing to market expansion.

Europe

Europe is also witnessing significant growth in the amyloidosis therapeutics market, driven by regulatory approvals and advances in treatment options. Countries like Germany, France, and the U.K. are expected to be key contributors to this growth. The National Amyloidosis Centre in the U.K., for instance, plays a central role in research and patient management, demonstrating the region's commitment to treating amyloidosis. In Germany, government initiatives are facilitating access to effective therapies, further boosting market prospects.

Market Drivers

Several factors are contributing to the growth of the amyloidosis therapeutics market:

Increased Awareness: There has been a growing awareness of amyloidosis among healthcare providers and the general population, leading to more frequent diagnoses.

Advancements in Diagnostic Technologies: The integration of advanced imaging techniques, such as cardiac MRI and nuclear imaging, has significantly improved early detection and diagnosis of amyloidosis.

Innovative Treatment Options: The approval and use of novel drugs such as tafamidis, patisiran, and vutrisiran have expanded treatment options for amyloidosis, particularly for ATTR and AL amyloidosis.

Market Restraints

Despite the growth prospects, the amyloidosis therapeutics market faces several challenges:

High Treatment Costs: The cost of treatments such as tafamidis and patisiran can be prohibitively expensive, which limits access for many patients, especially in countries with less-developed healthcare systems.

Diagnostic Complexity: The difficulty in diagnosing amyloidosis in its early stages, as the symptoms mimic those of other diseases, remains a significant challenge.

Limited Awareness in Developing Regions: While developed regions like North America and Europe benefit from extensive awareness and diagnostic tools, this is not the case in many developing regions, where amyloidosis remains underdiagnosed.

Market Opportunities

The amyloidosis therapeutics market presents several opportunities for growth:

AI in Diagnostics: The integration of artificial intelligence in diagnostic imaging is improving the speed and accuracy of amyloidosis detection, creating new avenues for early intervention.

Gene-Silencing Therapies: Emerging treatments like gene-silencing therapies and RNA-based drugs offer promising opportunities to target the root causes of amyloidosis at the molecular level.

Regional Market Expansion: With increasing government support in regions like Asia-Pacific, the market is expanding rapidly, especially in China and Japan, where regulatory approvals and awareness are on the rise.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35504

Reasons to Buy the Report

• Get a comprehensive analysis of the amyloidosis therapeutics market and its growth potential.
• Understand the dynamics driving the market and the factors hindering its growth.
• Gain insights into the key players and their strategies in the amyloidosis therapeutics market.
• Access to detailed market segmentation, including treatment types and end-user categories.
• Understand the regional trends and key developments in North America, Europe, and Asia-Pacific.

Frequently Asked Questions (FAQs)

• How big is the amyloidosis therapeutics market?
• Who are the key players in the global amyloidosis therapeutics market?
• What is the projected growth rate of the amyloidosis therapeutics market?
• What is the market forecast for amyloidosis therapeutics by 2032?
• Which region is estimated to dominate the amyloidosis therapeutics industry through the forecast period?

Company Insights

The amyloidosis therapeutics market is competitive, with a mix of established pharmaceutical companies and emerging biotech firms. Key players include:

• Pfizer Inc.
• Johnson & Johnson Services, Inc.
• Takeda Pharmaceutical Company Limited
• Prothena Corporation
• Ionis Pharmaceuticals

Recent Developments:

In March 2025, Alnylam Pharmaceuticals received U.S. FDA approval for AMVUTTRA® (vutrisiran) to treat transthyretin amyloidosis (ATTR-CM).

In February 2025, the European Commission granted marketing authorization for Acoramidis (Beyonttra) to treat wild-type or variant transthyretin amyloidosis (ATTR-CM).

In conclusion, the amyloidosis therapeutics market is positioned for substantial growth driven by advancements in diagnostic tools, therapeutic options, and expanding global awareness. The increasing adoption of AI in diagnostics and the development of innovative drug therapies are opening up new opportunities for better patient outcomes.

Read More Related Reports:

Spinal Stenosis Implant Market https://www.persistencemarketresearch.com/market-research/spinal-stenosis-implant-market.asp
Micro Plate Instruments Market https://www.persistencemarketresearch.com/market-research/micro-plate-instruments-market.asp
Endoscope Washer Disinfector Market https://www.persistencemarketresearch.com/market-research/endoscope-washer-disinfector-market.asp
Analytical Standards For Life Sciences Market https://www.persistencemarketresearch.com/market-research/analytical-standards-for-life-sciences-market.asp
Pelvic Trauma Management Market https://www.persistencemarketresearch.com/market-research/pelvic-trauma-management-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.